Completed PHASE1 INTERVENTIONAL 3-arm NCT00814489

Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults

A Study to Evaluate GlaxoSmithKline (GSK) Biologicals' Investigational Vaccination Regimen in Healthy Young Adults

Sponsor: GlaxoSmithKline

Conditions Haemophilus Influenzae Streptococcus Pneumoniae

Updated 7 times since 2017 Last updated: Jul 11, 2018 Started: Jan 8, 2009 Primary completion: May 4, 2009 Completion: Jun 10, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Haemophilus Influenzae and Streptococcus Pneumoniae, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 7 data snapshots since 2009. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Sep 2018 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Sep 2018 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Karlskrona, Sweden